Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167


Opening the LOX to bone metastasis: The role of secreted lysyl oxidase in skeletal recurrence of breast cancers.

Mohammed MK, Shao C, Luu HH, Haydon RC.

Genes Dis. 2015 Dec;2(4):288-290. doi: 10.1016/j.gendis.2015.08.004. Epub 2015 Sep 14. No abstract available.


Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527.

Freedman RA, Foster JC, Seisler DK, Lafky JM, Muss HB, Cohen HJ, Mandelblatt J, Winer EP, Hudis CA, Partridge AH, Carey LA, Cirrincione C, Moreno-Aspitia A, Kimmick G, Jatoi A, Hurria A.

J Clin Oncol. 2017 Feb;35(4):421-431. doi: 10.1200/JCO.2016.69.4182. Epub 2016 Dec 19.


A network-based phenotype mapping approach to identify genes that modulate drug response phenotypes.

Cairns J, Ung CY, da Rocha EL, Zhang C, Correia C, Weinshilboum R, Wang L, Li H.

Sci Rep. 2016 Nov 14;6:37003. doi: 10.1038/srep37003.


Platelet-Lymphocyte Ratio as a Useful Predictor of the Therapeutic Effect of Neoadjuvant Chemotherapy in Breast Cancer.

Asano Y, Kashiwagi S, Onoda N, Noda S, Kawajiri H, Takashima T, Ohsawa M, Kitagawa S, Hirakawa K.

PLoS One. 2016 Jul 29;11(7):e0153459. doi: 10.1371/journal.pone.0153459. eCollection 2016.


Toxicity Assessment of a Phase III Study Evaluating FEC-Doc and FEC-Doc Combined with Gemcitabine as an Adjuvant Treatment for High-Risk Early Breast Cancer: the SUCCESS-A Trial.

Schröder L, Rack B, Sommer H, Koch JG, Weissenbacher T, Janni W, Schneeweiss A, Rezai M, Lorenz R, Jäger B, Schramm A, Häberle L, Fasching PA, Friedl TW, Beckmann MW, Scholz C.

Geburtshilfe Frauenheilkd. 2016 May;76(5):542-550.


Pathological complete response as a surrogate for relapse-free survival in patients with triple negative breast cancer after neoadjuvant chemotherapy.

Li J, Chen S, Chen C, Di G, Liu G, Wu J, Shao Z.

Oncotarget. 2017 Mar 14;8(11):18399-18408. doi: 10.18632/oncotarget.9369.


Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.

Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L.

Nat Rev Clin Oncol. 2016 Nov;13(11):674-690. doi: 10.1038/nrclinonc.2016.66. Epub 2016 May 17. Review.


Trends in the Application of Postmastectomy Radiotherapy for Breast Cancer With 1 to 3 Positive Axillary Nodes and Tumors ≤5 cm in the Modern Treatment Era: A Retrospective Korean Breast Cancer Society Report.

Chang JS, Choi JE, Park MH, Jung SH, Choi BO, Park HS, Park S, Kim YB; Korean Breast Cancer Society.

Medicine (Baltimore). 2016 May;95(19):e3592. doi: 10.1097/MD.0000000000003592.


Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study.

Janni W, Harbeck N, Rack B, Augustin D, Jueckstock J, Wischnik A, Annecke K, Scholz C, Huober J, Zwingers T, Friedl TW, Kiechle M.

Br J Cancer. 2016 Apr 12;114(8):863-71. doi: 10.1038/bjc.2016.82. Epub 2016 Mar 31.


Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer.

Greenlee H, Crew KD, Capodice J, Awad D, Buono D, Shi Z, Jeffres A, Wyse S, Whitman W, Trivedi MS, Kalinsky K, Hershman DL.

Breast Cancer Res Treat. 2016 Apr;156(3):453-64. doi: 10.1007/s10549-016-3759-2. Epub 2016 Mar 25.


Efficacy of chemotherapy after hormone therapy for hormone receptor-positive metastatic breast cancer.

Mori R, Nagao Y.

SAGE Open Med. 2014 Nov 6;2:2050312114557376. doi: 10.1177/2050312114557376. eCollection 2014.


A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities.

Abraham JE, Hiller L, Dorling L, Vallier AL, Dunn J, Bowden S, Ingle S, Jones L, Hardy R, Twelves C, Poole CJ, Pharoah PD, Caldas C, Earl HM.

BMC Med. 2015 Dec 29;13:306. doi: 10.1186/s12916-015-0547-5.


Chemotherapy in Premenopausal Breast Cancer Patients.

Partridge AH.

Breast Care (Basel). 2015 Oct;10(5):307-10. doi: 10.1159/000441371. Epub 2015 Oct 21. Review.


Breast Cancer: State of the Art and New Findings.

Melcher C, Scholz C, Jäger B, Hagenbeck C, Rack B, Janni W.

Geburtshilfe Frauenheilkd. 2012 Mar;72(3):215-224.


Mammography screening in less developed countries.

Li J, Shao Z.

Springerplus. 2015 Oct 15;4:615. doi: 10.1186/s40064-015-1394-8. eCollection 2015. Review.


Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer.

Asano Y, Kashiwagi S, Onoda N, Noda S, Kawajiri H, Takashima T, Ohsawa M, Kitagawa S, Hirakawa K.

Ann Surg Oncol. 2016 Apr;23(4):1104-10. doi: 10.1245/s10434-015-4934-0. Epub 2015 Oct 28.


Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study.

Rahal S, Boher JM, Extra JM, Tarpin C, Charafe-Jauffret E, Lambaudie E, Sabatier R, Thomassin-Piana J, Tallet A, Resbeut M, Houvenaeghel G, Laborde L, Bertucci F, Viens P, Gonçalves A.

BMC Cancer. 2015 Oct 14;15:697. doi: 10.1186/s12885-015-1746-3.


A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer.

Iyengar NM, Fornier MN, Sugarman SM, Theodoulou M, Troso-Sandoval TA, D'Andrea GM, Drullinsky PR, Gajria D, Goldfarb SB, Comen EA, Lake DE, Modi S, Traina TA, Lacouture ME, Chen MF, Patil S, Baselga J, Norton L, Hudis CA, Dang CT.

Clin Breast Cancer. 2016 Apr;16(2):87-94. doi: 10.1016/j.clbc.2015.09.009. Epub 2015 Sep 25.


Do Recent Advances in Diagnostic and Therapeutic Procedures Negate the Benefit of Postmastectomy Radiotherapy in N1 Patients With a Low Risk of Locoregional Recurrence?

Chang JS, Lee J, Kim KH, Sohn JH, Kim SI, Park BW, Chung HC, Keum KC, Suh CO, Kim YB.

Medicine (Baltimore). 2015 Aug;94(33):e1259. doi: 10.1097/MD.0000000000001259.

Supplemental Content

Support Center